CANADA LIFE ASSURANCE Co Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

CANADA LIFE ASSURANCE Co raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 279,836 shares of the life sciences company's stock after purchasing an additional 13,563 shares during the quarter. CANADA LIFE ASSURANCE Co owned 0.18% of Illumina worth $37,382,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. WCM Investment Management LLC lifted its holdings in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after acquiring an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Illumina by 0.8% during the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Norges Bank purchased a new position in shares of Illumina during the fourth quarter worth $228,714,000. Bessemer Group Inc. grew its stake in shares of Illumina by 32,837.5% in the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in shares of Illumina by 245.7% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company's stock valued at $158,011,000 after buying an additional 840,423 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

NASDAQ ILMN traded up $1.58 during trading hours on Thursday, hitting $77.83. The company had a trading volume of 476,590 shares, compared to its average volume of 2,512,985. The business has a 50 day moving average of $82.95 and a 200-day moving average of $119.06. The company has a market cap of $12.32 billion, a PE ratio of -10.14, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ILMN. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price for the company. in a report on Friday, February 28th. TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and dropped their price objective for the company from $177.00 to $140.00 in a report on Friday, February 7th. Canaccord Genuity Group reduced their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, March 11th. Piper Sandler boosted their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Finally, Barclays reduced their price objective on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.